CN109336824B - Mek抑制剂的制备和包含mek抑制剂的制剂 - Google Patents

Mek抑制剂的制备和包含mek抑制剂的制剂 Download PDF

Info

Publication number
CN109336824B
CN109336824B CN201811124073.6A CN201811124073A CN109336824B CN 109336824 B CN109336824 B CN 109336824B CN 201811124073 A CN201811124073 A CN 201811124073A CN 109336824 B CN109336824 B CN 109336824B
Authority
CN
China
Prior art keywords
compound
crystalline
formula
mixture
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811124073.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109336824A (zh
Inventor
C.M.克雷尔
M.米森
D.A.尼德尔
W.H.帕钦格
M-c.沃尔夫
D.齐默尔曼
W.刘
P.J.斯滕格尔
P.尼科尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Novartis AG
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50488781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109336824(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Array Biopharma Inc filed Critical Novartis AG
Publication of CN109336824A publication Critical patent/CN109336824A/zh
Application granted granted Critical
Publication of CN109336824B publication Critical patent/CN109336824B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201811124073.6A 2012-10-19 2013-10-18 Mek抑制剂的制备和包含mek抑制剂的制剂 Active CN109336824B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261716169P 2012-10-19 2012-10-19
US61/716,169 2012-10-19
PCT/US2013/065633 WO2014063024A1 (en) 2012-10-19 2013-10-18 Preparation of and formulation comprising a mek inhibitor
CN201380063271.5A CN104870427B (zh) 2012-10-19 2013-10-18 Mek抑制剂的制备和包含mek抑制剂的制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380063271.5A Division CN104870427B (zh) 2012-10-19 2013-10-18 Mek抑制剂的制备和包含mek抑制剂的制剂

Publications (2)

Publication Number Publication Date
CN109336824A CN109336824A (zh) 2019-02-15
CN109336824B true CN109336824B (zh) 2022-11-11

Family

ID=50488781

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201811124073.6A Active CN109336824B (zh) 2012-10-19 2013-10-18 Mek抑制剂的制备和包含mek抑制剂的制剂
CN201810684986.7A Pending CN109456272A (zh) 2012-10-19 2013-10-18 Mek抑制剂的制备和包含mek抑制剂的制剂
CN201380063271.5A Active CN104870427B (zh) 2012-10-19 2013-10-18 Mek抑制剂的制备和包含mek抑制剂的制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201810684986.7A Pending CN109456272A (zh) 2012-10-19 2013-10-18 Mek抑制剂的制备和包含mek抑制剂的制剂
CN201380063271.5A Active CN104870427B (zh) 2012-10-19 2013-10-18 Mek抑制剂的制备和包含mek抑制剂的制剂

Country Status (23)

Country Link
US (7) US9238627B2 (https=)
EP (3) EP4306171A3 (https=)
JP (3) JP6385939B2 (https=)
CN (3) CN109336824B (https=)
AR (1) AR099630A1 (https=)
BR (1) BR112015008623B1 (https=)
CA (2) CA3079071C (https=)
CY (1) CY1122670T1 (https=)
DK (2) DK2909182T3 (https=)
ES (2) ES2971077T3 (https=)
FI (1) FI3702351T3 (https=)
HR (1) HRP20240033T1 (https=)
HU (2) HUE065433T2 (https=)
JO (1) JOP20130304B1 (https=)
LT (1) LT3702351T (https=)
PL (2) PL3702351T3 (https=)
PT (2) PT3702351T (https=)
RS (1) RS65117B1 (https=)
RU (2) RU2018127873A (https=)
SI (2) SI3702351T1 (https=)
SM (1) SMT202400044T1 (https=)
TW (1) TWI650316B (https=)
WO (1) WO2014063024A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR099630A1 (es) 2012-10-19 2016-08-10 Novartis Ag Preparación de un inhibidor de mek y formulación que lo comprende
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
MX387795B (es) * 2016-06-03 2025-03-19 Array Biopharma Inc Combinaciones farmaceuticas.
CN111646946A (zh) * 2017-11-14 2020-09-11 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑化合物及包含该化合物的组合物
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
WO2019139970A1 (en) * 2018-01-09 2019-07-18 Duke University Topical administration of mek inhibiting agents for the treatment of skin disorders
WO2020212832A1 (en) * 2019-04-16 2020-10-22 Alembic Pharmaceuticals Limited Process of preparation of benzimidazole compounds
WO2021116901A1 (en) * 2019-12-09 2021-06-17 Biocon Limited Forms of binimetinib and process for preparation thereof
AU2021358394A1 (en) 2020-10-05 2023-04-13 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma
CN112679438A (zh) * 2020-12-31 2021-04-20 武汉九州钰民医药科技有限公司 制备司美替尼的方法
EP4346826A4 (en) 2021-05-27 2025-04-30 Mirati Therapeutics, Inc. COMBINATION THERAPIES
WO2023084489A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
EP4460303A4 (en) * 2022-01-06 2025-07-23 Msn Laboratories Private Ltd R&D Center IMPROVED PROCESS FOR THE PREPARATION OF 5-[(4-BROMO-2-FLUOROPHENYL)AMINO]-4-FLUORO-N-(2HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE
WO2024003942A1 (en) * 2022-07-01 2024-01-04 Natco Pharma Limited An improved process for the preparation of selumetinib sulfate
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
FR3159741A1 (fr) 2024-03-04 2025-09-05 Pierre Fabre Medicament Formulation topique comprenant du binimetinib
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2355470C (en) * 1999-01-13 2008-09-30 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
CA2377092A1 (en) * 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
SG2013013339A (en) * 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
CA2532067C (en) * 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
US8039637B2 (en) 2005-06-23 2011-10-18 Array Biopharma Inc. Process for preparing benzimidazole compounds
EP1904061B1 (en) 2005-06-23 2018-12-26 Array Biopharma, Inc. SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS
WO2009018233A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
EP1966155A1 (en) * 2005-12-21 2008-09-10 AstraZeneca AB Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
WO2009064675A1 (en) 2007-11-12 2009-05-22 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
BRPI0925050A2 (pt) * 2009-04-21 2015-08-04 Novartis Ag Compostos heterocíclicos como inibidores de mek
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
JP2014528928A (ja) 2011-09-01 2014-10-30 ノバルティス アーゲー ヌーナン症候群の治療のための有機化合物の使用
AR099630A1 (es) 2012-10-19 2016-08-10 Novartis Ag Preparación de un inhibidor de mek y formulación que lo comprende

Also Published As

Publication number Publication date
DK2909182T3 (da) 2020-02-17
US10398683B2 (en) 2019-09-03
JP2019194272A (ja) 2019-11-07
WO2014063024A1 (en) 2014-04-24
PL3702351T3 (pl) 2024-04-02
SI3702351T1 (sl) 2024-03-29
US9382212B1 (en) 2016-07-05
US9598376B2 (en) 2017-03-21
EP2909182A1 (en) 2015-08-26
RU2018127873A (ru) 2019-03-14
SI2909182T1 (sl) 2020-03-31
EP3702351A1 (en) 2020-09-02
LT3702351T (lt) 2024-01-10
TW201427956A (zh) 2014-07-16
US10729678B2 (en) 2020-08-04
US20160168102A1 (en) 2016-06-16
ES2772498T3 (es) 2020-07-07
US9562016B2 (en) 2017-02-07
US20180296533A1 (en) 2018-10-18
TWI650316B (zh) 2019-02-11
JP2018135399A (ja) 2018-08-30
AR099630A1 (es) 2016-08-10
JP6737838B2 (ja) 2020-08-12
EP3702351B1 (en) 2023-11-22
CN104870427B (zh) 2018-10-23
EP4306171A3 (en) 2024-04-03
DK3702351T3 (da) 2024-01-29
CY1122670T1 (el) 2021-03-12
SMT202400044T1 (it) 2024-03-13
PT3702351T (pt) 2024-01-17
HRP20240033T1 (hr) 2024-03-29
CA3079071C (en) 2022-06-07
BR112015008623A2 (pt) 2017-07-04
FI3702351T3 (fi) 2024-01-24
JP2016503391A (ja) 2016-02-04
ES2971077T3 (es) 2024-06-03
CA2888474C (en) 2021-03-02
JP6385939B2 (ja) 2018-09-05
HUE047708T2 (hu) 2020-05-28
US9980944B2 (en) 2018-05-29
CA3079071A1 (en) 2014-04-24
CN104870427A (zh) 2015-08-26
RU2015118572A (ru) 2016-12-20
RS65117B1 (sr) 2024-02-29
US20160168104A1 (en) 2016-06-16
CA2888474A1 (en) 2014-04-24
BR112015008623B1 (pt) 2022-10-25
JOP20130304B1 (ar) 2021-08-17
US20140128442A1 (en) 2014-05-08
US20200171002A1 (en) 2020-06-04
US9238627B2 (en) 2016-01-19
EP2909182A4 (en) 2016-07-06
PL2909182T3 (pl) 2020-06-01
US20170231963A1 (en) 2017-08-17
HK1214254A1 (en) 2016-07-22
CN109336824A (zh) 2019-02-15
PT2909182T (pt) 2020-03-02
RU2669391C2 (ru) 2018-10-11
CN109456272A (zh) 2019-03-12
US20160168103A1 (en) 2016-06-16
HUE065433T2 (hu) 2024-05-28
EP2909182B1 (en) 2019-12-04
EP4306171A2 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
CN109336824B (zh) Mek抑制剂的制备和包含mek抑制剂的制剂
CN114846006A (zh) 杂环化合物及其制备方法和用途
WO2019206155A1 (zh) Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用
HK40005916A (en) Preparation of and formulation comprising a mek inhibitor
HK40108420A (en) Formulation comprising a mek inhibitor
WO2023165501A1 (zh) Azd5305的晶型及其制备方法和用途
HK1214254B (en) Preparation of and formulation comprising a mek inhibitor
US10759798B2 (en) ABT-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230323

Address after: Colorado, USA

Patentee after: Array BioPharma Inc.

Address before: Basel, SUI

Patentee before: NOVARTIS AG

Patentee before: Array BioPharma Inc.